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Two insulin types existing in the market are human and analog insulin, of which the human insulin is 
cheaper than that of analog. Despite such price disparity, the insulin analog in 2012-2017 is 
administered to patients more than human insulin. Medical practitioners at Medistra Hospital have no 
longer prescribed human insulin since 2014. This research's objectives were to evaluate the medication 
profile, compare cost profile, and clinical outcome of providing information for decision-makers to 
determine insulin administration policy in hospitals. The research subjects were type-2 diabetes 
mellitus (T2D) outpatients at Medistra Hospital. The data collection was conducted retrospectively, 
taking samples of 121 outpatients, of which 83 outpatients were evaluated for their clinical outcome. 
The medication profile data were collected from the medicine administration at the Hospital Pharmacy 
Installation. The clinical outcome data, such as fasting plasma glucose (FPG), two-hour postprandial 
plasma glucose (2HPP), and Hemoglobin A1c (HbA1c), were garnered from the patients' medical 
records. The cost data were collected from the outpatients' payment receipts provided by the Hospital's 
Financial Department. Kolmogorov Smirnov normality test was applied in this research. The single 
human insulin's clinical outcome resulted in FPG as much as 115±6.52, 2HPP as much as 176±4.43, 
and HbA1c as much as 7.63±0.47. Meanwhile, the clinical outcome of single analog insulin resulted 
in FPG as much as 108±13.19, 2HPP as much as 159±19.93, and HbA1c as much as 6.61±1.28. 
Kruskal Wallis Test was applied to find a statistical difference between the clinical outcome and the 
cost. The research result suggests that after Mann Whitney Test, the human and analog insulin were 
not significantly different seen from the clinical outcome result showing FPG (p=0.676), 2HPP 
(p=0.175), HbA1c (p=0.0445), and from the cost result (p=0.795). Furthermore, the research also 
shows that the average cost of 30-day medication of single human insulin was Rp3,190,997.43, while 
one of analog insulin was Rp3,188,832.35. In conclusion, the study finds out that human and analog 
insulin were not significantly different if seen from the cost (p=0.795).  
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INTRODUCTION 
Diabetes mellitus (thereafter called DM) 
is a chronic disease caused by the pancreas' 
insufficient insulin, which eventually 
increases the glucose concentration in blood 
and, consequently, such high concentration 
damages many-body systems, particularly 
blood vessels and nerve system (1).  
According to the International Diabetes 
Foundation, the number of DM patients 
worldwide reached 371 million, with 4.6 
million mortalities (2). World Health 
Organization (WHO) predicted that the 
number of DM patients in Indonesia would 
increase from 8.4 million in 2000 to 21.3 
million in 2030 (3). The data in 2014 showed 
that the number of DM patients in Indonesia 
reached 422 million, indicating a significant 
increase if compared to 108 million in 1980 
(4). The prevalence of diabetes mellitus in 
adult patients in the world had doubled since 
1980, rising from 4.7% to 8.5% (5), showing 
that there was an increase in related-risk 
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factors, such as body weight or obesity. Over 
the last few years, the prevalence of DM has 
increased more rapidly in low-income 
countries than in high-income ones (4). 
Diabetes Mellitus is categorized into two 
types, they are Type-1 Diabetes Mellitus 
(T1D), also called insulin-dependent DM 
(IDDM), caused by the insufficient insulin 
secretion produced by beta-cell pancreas, and 
Type-2 Diabetes Mellitus (T2D), also called 
non-insulin-dependent DM (NIDDM), caused 
by the decrease of target tissue sensitivity to 
the insulin (6). The objectives of DM therapy 
is to reduce the symptoms of hyperglycemia 
complication, such as retinopathy, 
nephropathy, neuropathy, and to increase the 
quality and quantity of patients' lives. 
Worsening conditions to DM patients might 
happen due to their blood sugar instability. 
Diabetes might also cause complications such 
as hypertension, heart attack, and kidney 
failure (7). Indonesia Endocrinologists' 
Association (PERKENI, Perhimpunan 
Endokrinologi Indonesia) suggested that early 
therapy for DM patients should be 
administered orally. However, if the treatment 
of three oral medication combination has been 
done, insulin therapy should be carried out. 
Insulin therapy can be directly administered to 
DM patients if their condition's laboratory 
data show HbA1c≥10% or FPG≥300 mg/dl 
with metabolic disorders (8). At present, the 
choices of therapy available, among others, 
are biguanides medication, sulfonylurea, 
pioglitazone, alpha-glucosidase inhibitors, 
GLP-1 receptor agonists, and insulin (6). 
Most Type-2 DM patients do not require 
insulin therapy. However, almost 30% of DM 
patients need insulin therapy in addition to 
oral hypoglycemic therapy (9). 
Insulin is a vital medication for millions 
of Type-2 DM patients and a hundred million 
more. For more than a hundred years, insulin 
has been used for clinical therapy, but its 
availability is far from expectation (10). 
Based on its production method, there are two 
types of insulin, namely, analog and human 
insulin. Human insulin is taken from humans 
or made of synthetically resembling human 
amino-acid chain utilizing biosynthetic 
technology of DNA recombinant using 
bacteria or modified semisynthetic of porcine 
insulin (11). Analog insulin is produced using 
DNA recombinant technology to achieve a 
better absorption effect and longer therapy 
duration (12). Analog insulin is amino-acid 
insulin modified to give a rapid and more 
durable glucose reduction effect than human 
insulin (12). Human and analog insulin is 
comparably safer than inventors' products 
(natural animal insulin) (13). This safety is 
related to the purification process and 
hypoglycemia side-effect induced by natural 
animal insulin. However, it is found, in some 
cases, that human insulin might also cause 
hypoglycemia side-effects. This is because 
the maximum serum concentration (Cmax) in 
blood for human insulin is longer than the 
analog one (14). 
Human and analog insulin have similar 
efficacy in reducing glucose levels. 
Nevertheless, it was found that the use of 
human insulin in hypoglycemia cases was 
lower than the analog insulin (15). The use of 
human or analog insulin calculated its safety 
risk. Some research found an increased risk of 
cancer in the use of glargine insulin (16) (17), 
although, in some other research, it was 
refuted that there was no strong evidence of 
cancer risk increase in the use of analog 
insulin. 
According to an article in the National 
Institute of Clinical Excellence (NICE), 
human insulin is recommended more than 
analog insulin. The analog insulin is 
recommended for DM patients who cannot 
perform human insulin self-injection and 
those who suffer from hypoglycemia. Analog 
insulin may reduce the injection frequency 
due to its longer durability than human 
insulin. However, it was found that the analog 
insulin's effectiveness with long onset time 
was not significantly different from human 
insulin (19). Many countries have heavily 
invested in health budgets to ensure the use of 
analog insulin to be as effective as human 
insulin. 
Insulin is a medication vital for DM 
patient therapy and is included in the shortlist 
of drugs covered by health insurance in many 
                                           Jurnal Profesi Medika: Jurnal Kedokteran dan                             
ISSN 0216-3438 (Print). ISSN 2621-1122 (Online)                                                                                               Kesehatan 
 
Vol. 14 No 2 2020 DOI:   http://dx.doi.org/10.33533/jpm.v14i2.2007                                                            173 
 
countries (21). In Indonesia, insulin was listed 
as a medication covered by National Health 
Insurance (JKN, Jaminan Kesehatan 
Nasional). According to the Ministry of 
Health in 2015, DM was one of the ten major 
diseases that had absorbed 33% of the total 
budget, as much as 3.27 trillion rupiahs. The 
budget covered the patients diagnosed with 
diabetes, diabetes with complications, and 
diabetes as comorbidities (22). Doctors' role 
in choosing the types of insulin therapy 
determined the degree to which JKN covered 
the treatment cost. Medistra Hospital is one of 
the private hospitals not collaborating with 
JKN so that the patients must pay for 
themselves or rely on their private insurance. 
Private insurance companies, however, only 
pay the claim once per month. 
DM was one of the 5 most diseases 
suffered by patients treated in Medistra 
Hospital. The number of HbA1c increased 
every year. In Medistra Hospital, the type of 
insulin available was an analog one. The use 
of human insulin was reportedly decreasing. 
Since 2014, human insulin had not been 
prescribed by the doctors in Medistra 
Hospital. 
The price of analog insulin in Medistra 
Hospital was reportedly higher than human 
insulin. A patient without health insurance 
using analog insulin therapy routinely would 
likely spend more money, which eventually 
impacted the increasing cost of the patient's 
treatment. This was where the research 
entitled "Profile Evaluation of Medication, 
Cost Comparison, and Clinical Outcome of 
Human and Analogue Insulin Treatment to 
Type-2 Diabetes Mellitus Outpatients at 
Medistra Hospital" found its rationale. 
 
RESEARCH METHOD 
The research was conducted as a 
longitudinal time series. The research data 
were collected from January 2012 to 
December 2013. The data were collected 
retrospectively from the patients' medical 
records, particularly the patients treated using 
human and analog insulin. The data were 
garnered in medication profile, clinical 
outcome (FPG, 2HPP, and HBA1c), 
medication cost, and the outpatients' financial 
records during their medical treatment. The 
data garnered were qualitatively and 
quantitatively analyzed. The sampling 
method applied was total sampling. The data 
were taken from the outpatients' medical 
records, medication from pharmacy 
installation, and cost from outpatients' 
administration unit. 
Variables in the research are as follows: 
a. Free (independent) variables: human and 
analog insulin 
b. Dependent variables: medication profile, 
medication cost, clinical outcome. 
The population comprises all Type-2 
DM outpatients covered by private health 
insurance and personal payment from 
January 2012 to December 2013.  
 Based on the patients' medical records, 
the research population was 176 Type-2 DM 
outpatients using human and analog insulin. 
Applying Kriejcie-Morgan, the research 
found data sampling as many as 121 patients. 
The patients were selected based on the 
following criteria: 
1. Inclusion criteria 
a. Outpatients diagnosed as Type-2 DM 
from January 2012-December 2013 
b. Type-2 DM outpatients with insulin 
therapy having a routine control from 
January 2012 to December 2013 
c. Outpatients having insulin therapy for 
at least 3 (three) times 
2. Exclusion criteria: 
Outpatients diagnosed as Type-2 DM 
from January 2012-December 2013, but 
having the following shortcomings: 
a. Incomplete laboratory data 
b. Incomplete medication data 
c. Not treated with insulin 
d. Incomplete cost medication 
 
RESEARCH FINDINGS 
Profile evaluation of the patients can be 
found in the demography data. 
From the total sample of Type-2 DM 
outpatients using insulin, 121 patients were 
taken as the research subjects. 
 
                                           Jurnal Profesi Medika: Jurnal Kedokteran dan                             
ISSN 0216-3438 (Print). ISSN 2621-1122 (Online)                                                                                               Kesehatan 
 
Vol. 14 No 2 2020 DOI:   http://dx.doi.org/10.33533/jpm.v14i2.2007                                                            174 
 
Table 1. The demography of type-2 DM 
outpatients using human insulin, analog 
insulin, and combined insulin (human and 






According to Rahmi Yosmar and Agus 
the number of women who have diabetes was 
higher than men, which is 36:35. The subjects 
of the research in this study were mostly 
female, although the difference was not 
significant. Women are perilous to suffer 
from DM than men. This is because the Low-
Density Lipoprotein (LDL) or triglycerides in 
women is higher than men. Type-2 diabetes is 
primarily due to females' and males' different 
activities and lifestyles, affecting the disease. 
These are the factors that cause diabetes 
mellitus (37). 
The age of the subjects of the research 
ranged from 55 to 64 years old. The data were 
                                           Jurnal Profesi Medika: Jurnal Kedokteran dan                             
ISSN 0216-3438 (Print). ISSN 2621-1122 (Online)                                                                                               Kesehatan 
 
Vol. 14 No 2 2020 DOI:   http://dx.doi.org/10.33533/jpm.v14i2.2007                                                            175 
 
supported by Kusnanto' research stating that 
the respondents taken in his research ranged 
from 45-65 years old. 
According to table V.3, most Type-2 DM 
patients at Medistra Hospital were 
categorized into Non-Insulin Dependent 
Without Complication. However, the high 
complication caused by diabetes mellitus was 
neuropathy. The data of infectious disease 
control released by the Ministry of Health 
stated that the high percentage of 
complications caused by diabetes mellitus at 
Cipto Mangunkusumo Hospital was 
neuropathy (39). The present study is similar 
to Muthiah's, stating that neuropathy was 
likely to be found in DM patients around 55 
years old (40). 
The research showed that 90.8% of DM 
outpatients came to a polyclinic before 
commencing their further treatment to the 
hospital. This indicated that most patients 
were not admitted through the Emergency 
Room. 
The research showed that the high 
number of type-2 DM outpatients based on 
education level was bachelor's degree 
students. This is supported by the 
RISKESDAS (Basic Health Research) 2018, 
stating that the highest prevalence of DM 
patients based on education level was 
associate degree level 1, level 2, level 3, and 
university students. 
The number of smoking patients was 
more than non-smoking ones. Smoking habit 
may worsen the DM because nicotine can 
release insulin due to the catecholamine 
hormone activity that prevents the work of 
betta cells of the pancreas and causes insulin 
resistance (41). Maria Redita, in her research, 
explained that there was a weak yet significant 
relationship between the length of smoking 
and the increased glucose level. This is due to 
the fact that nicotine exposure increased 
mTOR activity and IRS-1 Ser636 
Phosphorylation, which eventually caused the 
resistance of insulin receptors and insulin 
secretion dysfunction. All the patients in this 
research were not alcoholics. 
The most comorbidities suffered by the 
patients in this research were hypertension 
and one other disease. The number and the 
types of comorbidities of type-2 DM patients 
might affect the amount and types of non-DM 
medication consumed by the patients. The 
hospital visits frequency of the patients to be 
taken as the sample was 6-8 times. 
The number of hypoglycemic cases in 
2012 was 2. They are the uses of human 
insulin and the combination of human and 
analog insulin. 
The marital status of type-2 diabetes 
patients in 2012 and 2013 taken in this 
research were married. This is supported by 
Kusnanto's research stating that the highest 
percentage of the respondents' marital status 
in his research was married (38). 
 
Treatment Profile 
1. The number of medication 
a. The average number of medications per 
patient 
The average number of medication items 
was obtained from the medication consumed 
by the type-2 DM patients in 2012 and 2013 
at Medistra hospital. The average number of 
medications per patient was 2 DM 
medication, three non-DM medication, and 1 
medical tool item. Firni et al. stated that based 
on the data of DM medication use in 2014, 
there were four or more medications with 3-
OAD composition and insulin (43). Some 
samples showed that the more medication 
items were consumed, the more patients with 
comorbidities were. However, some other 
samples showed that the comparison of the 
total number of medication items was not 
directly proportional to comorbidities. This is 
because doctors prescribed supplements as an 
additional therapy to the type-2 DM 
outpatients. 
2. DM and Non-DM Medication Proportion 
Diabetes mellitus medication is a drug 
used for therapy purposes, while the non-DM 
medication is for other diseases suffered by 
DM patients. The patients' average of DM 
medication consumed was 35.45%, while 
non-DM medicine was 64.55%. The patients' 
DM medication items were 2 items, while the 
non-DM medications were 3 items. This 
showed that the use of non-DM medication 
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type was more than that of the DM one. This 
is due to the patients' comorbidities and the 
additional supplement prescribed for type-2 
DM patients. The OAD group most frequently 
used in this research, 50%, was biguanides 
with Glucophage 500 mg's trademark. 
 
Insulin use proportion 
a. Prescription of insulin based on the insulin 
types 
The most prescribed insulin types in 
2012 were single-human insulin, while the 
most prescribed insulin types in 2013 were the 
combination of analog and human insulin. 
b. Prescription of insulin types based on the 
durability 
 In 2012 the type of insulin most 
frequently used was the short-acting human 
insulin group. Meanwhile, in 2013 the most 
frequently used insulin type was the 
combination of long-acting and rapid-acting 
analog insulin groups. 
 
Clinical Outcome 
Single analog insulin resulted in a better 
clinical outcome with fasting plasma glucose 
(FPG) of 108, which was considered 
exceptionally low. The better value of the 
clinical outcome for two-hour postprandial 
plasma glucose (2HPP) was combined-analog 
insulin and the oral antidiabetic drug (OAD) 
with the lowest 2HPP of 166. The better 
clinical outcome result for HbA1c was single-
analog insulin with an HbA1c of 6.61, which 
was considered exceptionally low. Compared 
to single-human insulin, the single-analog 
insulin resulted in a better clinical outcome for 
FPG, 2HPP, and HbA1c. The data can be 
found in table V.14. Meanwhile, the 
combination of analogs insulin resulted in a 
better outcome for FPG, 2HPP, and HbA1c 
than the combination of human-analog 
insulin. However, the combination of analog 
insulin and OAD shows a better result than the 
combination of human insulin and OAD. 
After the clinical outcome for each 
insulin type was calculated, the Kruskal-
Wallis statistic test was conducted to ensure 
there were differences in statistics. 
Based on the Kruskal-Wallis table test, it 
was found that for the type-2 DM outpatients 
at Medistra Hospital in 2012-2013, the FPG 
difference between insulin types was 67.594 
with a probability value (p-value) of 0.000. 
Since the p-value was 0.000 < α value = 0.05, 
H0 hypothesis was rejected. This study 
showed significant differences in the average 
of FPG between insulin types (at least there 
was one significantly different insulin group). 
The FPG test showed that the combined 
insulin consisting of analog insulin and OAD 
produced a better result of 194.33. 
 The research found that for outpatients 
at Medistra Hospital in 2012-2013, the 2HPP 
discrimination test between insulin types 
using the Kruskal-Wallis test was 66.780 with 
a p-value of 0.000. Since the p-value was 
0.000 < α value = 0.05, H0 hypothesis was 
rejected. This study showed significant 
differences in the average of 2HPP between 
insulin types (at least there was one 
significantly different insulin group). The 
2HPP test showed that the combined insulin 
consisting of analog insulin and OAD 
produced a better result of 198.82. 
For the type-2 DM outpatients at 
Medistra Hospital in 2012-2013, it was found 
that based on the Kruskal-Wallis test, the 
difference of HbA1c between insulin types 
was 25.806 with the p-value of 0.000. Since 
the p-value was 0.000 < α value = 0.05, H0 
hypothesis was rejected. This study showed 
significant differences in the average of 
HbA1c between insulin types (at least there 
was one significantly different insulin group). 
The HbA1c test result showed the best 
different outcome between the combined 
insulin consisting of single analog insulin 
with a value of 62.47. 
 After the Kruskal-Wallis test showed a 
different result, the Mann-Whitney test was 
conducted to see whether there was a 
significantly different insulin pair with a p-




Based on the Kruskal-Wallis test, it was 
found that for type-2 DM outpatients at 
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Medistra Hospital in 2012-2013, the 
discrimination test result for the medication 
cost between insulin types was 143.442, the p-
value of 0.000. Since the p-value was 0.000 < 
α value = 0.05, H0 hypothesis was rejected. 
This study showed a significant difference in 
the average treatment cost between insulin 
types (at least one significantly different 
insulin group). 
Based on the Mann-Whitney cost test, 
there were four insignificantly different 
insulin pairs and 11 significantly different 
insulin pairs. The insulin pair is significantly 
different if the p-value was < 0.05. The 
significant difference was when the use of 
insulin had a significant effect on medication 
cost.  
The comparison between single-human 
insulin and single-analog insulin was not 
significantly different. The medication cost 
average of single-human insulin was around 
Rp3.190.997,43, while the single-analog 
insulin was slightly cheaper, which was 
around Rp3.188.832,15. The difference 
percentage of medication cost between single 
human insulin and analog insulin was 0.07%. 
Although human insulin was cheaper than an 
analog one, the medication cost for human 
insulin was more expensive than analog 
insulin. 
The comparison between human-
analogue insulin and analogs insulin did not 
show a significant difference. The medication 
cost for human-analog insulin was 
Rp4.033.429,81, while analogs insulin was 
Rp3.924.517,01. The difference percentage 
between human-analog insulin and analogs 
insulin was 2.70%. 
  Comparing the combination of human 
insulin-oral antidiabetic drugs (OAD) and 
the combination of analog insulin-OAD 
showed a significant difference. The 
medication cost for human insulin and OAD 
treatment was Rp3.241.515,46, while the 
cost for analog insulin and OAD treatment 
was Rp2.981.739,44. The difference 
percentage between human insulin-OAD and 
analog insulin-OAD was 8.01%. 
 The result showed no significant 
difference between the medication cost for 
single human insulin and single analog insulin 
and the combination of human-analog insulin 
group and the variety of analogs insulin 
group. The result showed, however, that there 
was a significant difference in the medication 
cost for the human insulin-OAD and the 
analog insulin-OAD. This finding did not 
confirm the hypothesis stating that human 




Based on the research findings, it can be 
concluded that 
1. Single-human insulin and analog insulin 
show a not significantly different result for the 
clinical outcome and medication cost. 
2. The combination of human insulin-OAD 
and analog insulin-OAD shows an 
insignificant difference for the clinical 
outcome, yet a significant difference for the 
medication cost. The medication cost for 
analog insulin-OAD is cheaper than human 
insulin-OAD with a better clinical outcome. 
3. The combination of analogs insulin and the 
combination of human-analog insulin shows a 
significantly different result for the fasting 
plasma glucose (FPG) clinical outcome. 
However, they show an insignificantly 
different result for the two-hour postprandial 
plasma glucose (2HPP) and HbA1c. 
Meanwhile, the medication cost shows an 
insignificantly different result. The 
combination of analogs shows a better FPG 
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